Clinical trial
An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
NCT00332917 · Solvay Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00332917 |
|---|---|
| Title | An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients |
| Official title | An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients |
| Lead sponsor | Solvay Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Early Stage Parkinson's Disease |
| Intervention type | Drug |
| Interventions | Pardoprunox |
| Enrollment | 224 |
| Start date | Feb 1, 2007 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Jun 2, 2006 |
| Last update posted | Jan 26, 2009 |
| Countries | Argentina, Belgium, Bulgaria, Canada, Chile, Colombia, Croatia, Finland, India, Israel, Mexico, New Zealand and 9 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: